Biomedical Engineering Reference
In-Depth Information
events in a relevant primate model early in preclinical
development using the final BiTE antibody drug candidate
will greatly facilitate future selection and development of T-
cell-engaging antibodies.
15. Kiewe P, Hasmuller S, Klahert S, Heinrigs M, Rack B, Marme
A, et al. (2008) Clin. Cancer Res. 12, 3085-3091.
16. Ruf P, Kluge M, Jager M, Burges A, Volovat C, Heiss MM, et
al. (2010) Pharmacokinetics, immunogenicity and bioactivity
of the therapeutic antibody catumaxomab intraperitoneally
administered to cancer patients. Br. J. Clin. Pharmacol. 69,
617-625.
17. Ridgway JB, Presta LG, Carter P. (1996) “Knobs-in-holes”
engineering of antibody CH3 domains for heavy chain hetero-
dimerization. Protein Eng. 9, 617-621.
18. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR,
et al. (2010) Development of a two-part strategy to identify a
therapeutic human bispecific antibody that inhibits IgE recep-
tor signalling. J. Biol. Chem. 285, 20850-20859.
19. Gunasekaran K, Pentony M, Shen M, garrett L, Forte C,
Woodward A, et al. (2010) Enhancing antibody Fc heterodimer
formation through electrostatic steering effects: applications to
bispecific molecules and monovalent IgG. J. Biol. Chem. 285,
19637-19646.
20. Wranik B. (2010) Keystone Conference on Advances in Bio-
pharmaceuticals, Keystone, CO, 2010 Jan 10.
21. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al.
(2010) SEEDbodies: fusion proteins based on strand-exchange
engineered domain (SEED) CH3 heterodimers in an Fc ana-
logue platform for asymmetric binders or immunofusions and
bispecific antibodies. Protein Eng. Des. Sel. 23, 195-202.
22. Klein C. (2010) Antibody Engineering Conference, San Diego,
CA, 2010 Dec 2010.
23. Throsby M. (2010) Third Annual Antibody Engineering and
Therapeutics Asia, Shanghai, China, 2010 Nov 11.
24. Schuurman J. (2010) Third Annual Antibody Engineering and
Therapeutics Asia, Shanghai, China, 2010 Nov 11.
25. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. (1989)
Binding activities of a repertoire of single immunoglobulin
variable domains secreted from Escherichia coli. Nature 341,
544-546.
26. Hamblin P. (2010) Sixth Annual PEGSummit, Boston, MA,
2010 May 20-21.
27. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K,
et al. (2009) Variants of the antibody herceptin that interact
with HER2 and VEGF at the antigen binding site. Science 323,
1610-1614.
28. Fuh G. (2010) 25th Annual Meeting of International Society
for Biological Therapy of Cancer, Washington, 2010 Oct 2.
29. Lum LG, Davol PA. (2005) Retargeting T cells and immune
effector cells with bispecific antibodies. Cancer Chemother.
Biol. Response Modif. 22, 273-291.
30. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, YoungWB,
et al. (2006) Human T cells armed with Her2/neu bispecific
antibodies divide, are cytotoxic, and secrete cytokines with
repeated stimulation. Clin. Cancer Res. 12, 569-576.
31. Lum L. (2010) Sixth Annual PEGSummit, Boston, MA, 2010
May 20-21.
32. Fitzgerald K. (2010) Sixth Annual PEGSummit, Boston, MA,
2010 May 20.
REFERENCES
1. Milstein C, Cuello AC. (1983) Hybrid hybridomas and their
use in immunohistochemistry. Nature 305, 537-540.
2. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. (1995)
Preferential species-restricted heavy/light chain pairing in
rat/mouse quadromas. Implications for a single-step purifica-
tion of bispecific antibodies. J. Immunol. 155, 219-225.
3. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO,
Ivanchenko VV, et al. (2010) The trifunctional antibody catu-
maxomab for the treatment of malignant ascites due to epi-
thelial cancer: results of a prospective randomized Phase II/III
trial. Int. J. Cancer 127, 2209-2222.
4. Brennan M, Davison PF, Paulus H. (1985) Preparation of
bispecific antibodies by chemical recombination of monoclo-
nal immunoglobulin G1 fragments. Science 229, 81-83.
5. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V,
Deo Y, et al. (1995) Phase Ia/Ib trial of bispecific antibody
MDX-210 in patients with advanced breast or ovarian cancer
that overexpress the proto-oncogene HER-2/neu. J. Clin.
Oncol. 13, 2281-2292.
6. Staerz UD, Kanagawa O, Bevan MJ. (1985) Hybrid antibodies
can target sites for attack by T cells. Nature 314, 628-631.
7. Corvalan JR, Smith W. (1987) Construction and characteriza-
tion of a hybrid-hybrid monoclonal antibody recognising both
carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer
Immunol. Immunother. 24, 127-132.
8. Carter P. (2001) Bispecific human IgG by design. J. Immunol.
Methods 248, 7-15.
9. Kufer P, Lutterbuese R, Baeuerle PA. (2004) A revival of
bispecific antibodies. Trends Biotechnol. 22, 238-244.
10. Muller D, Kontermann RE. (2007) Recombinant bispecific
antibodies for cellular cancer immunotherapy. Curr. Opin.
Mol. Ther. 9, 319-326.
11. Van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker
WK, Martinez-Martinez P, Vermeulen E, et al. (2007) Anti-
inflammatory activity of human IgG4 antibodies by dynamic
Fab arm exchange. Science 317, 1554-1557.
12. MouquetH, ScheidJF, ZollerMJ,KrogsgaardM,OttRG, Shukair
S, et al. (2010) Polyreactivity increases the apparent affinity of
anti-HIVantibodies by heteroligation. Nature 467, 591-595.
13. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW,
Heiss MM. (2009) Induction of anti-tumor immunity by
trifunctional antibodies in patients with peritoneal carcinoma-
tosis. J. Exp. Clin. Cancer Res. 14, 18.
14. Seimetz D, Lindhofer H, Bokemeyer C. (2010) Development
and approval of the trifunctional antibody catumaxomab (anti-
EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Cancer Treat. Rev. 36, 458-467.
Search WWH ::
Custom Search